Key Takeaways
- • Hike Medical secured $22.5 million in combined seed and Series A funding to automate the durable medical equipment (DME) and orthotics/prosthetics supply chain from referral through dispense.
- • Saga Ventures led the round with participation from Indicator Ventures, Fifth Down Capital, RiverPark Ventures, strategic investor Orthofeet, Inc., and notable angel investors including Monaco CEO Sam Blond and former New England Patriots head coach Jerod Mayo.
- • The company's AI-powered platform integrates back-office automation, point-of-care clinical tools, and in-house manufacturing to reduce wait times, lower remake rates, and improve care personalization across the DME supply chain.
- • The funding reflects investor confidence in addressing inefficiencies within the $30+ billion U.S. DME market, where fragmented supply chains and manual processes have historically constrained patient access and outcomes.
Summary
Hike Medical announced a $22.5 million seed and Series A funding round designed to accelerate automation across the fragmented durable medical equipment (DME) supply chain. The San Francisco-based company targets orthotics, prosthetics, and broader DME categories by consolidating historically disconnected workflows—from initial physician referral through final patient dispensing—into a unified technology platform.
Saga Ventures partner Max Altman led the investment round, joined by institutional backers Indicator Ventures, Fifth Down Capital, and RiverPark Ventures. The funding syndicate also included Orthofeet, Inc., positioning itself as both strategic investor and commercial partner, signaling potential early-stage distribution or integration pathways. The investor roster extends to prominent angel participants: Monaco CEO Sam Blond and Jerod Mayo, the former head coach of the New England Patriots and Super Bowl champion, underscoring cross-sector interest in healthcare supply chain efficiency.
Hike Medical's core value proposition centers on three integrated layers: AI-powered back-office automation to streamline administrative workflows, point-of-care clinical tools deployed at patient touchpoints, and proprietary in-house manufacturing capabilities. Management claims this architecture delivers measurable operational improvements—shorter patient wait times, reduced remake rates (a significant cost driver in orthotics and prosthetics), and enhanced personalization of device-based care. The company positions itself at the intersection of clinical outcomes and supply chain efficiency, a combination that addresses both provider economics and patient access constraints that have long plagued the DME sector.
The funding announcement reflects broader venture investor appetite for healthcare infrastructure plays targeting regulatory-protected, recurring-revenue markets. The DME sector, anchored by Medicare/Medicaid reimbursement frameworks and physician referral volumes, offers structural demand insulation. Hike's focus on automation and manufacturing integration addresses a specific pain point: the fragmented vendor ecosystem and manual processes that have historically extended care delivery timelines and inflated operational costs for providers.
Saga Ventures partner Max Altman led the investment round, joined by institutional backers Indicator Ventures, Fifth Down Capital, and RiverPark Ventures. The funding syndicate also included Orthofeet, Inc., positioning itself as both strategic investor and commercial partner, signaling potential early-stage distribution or integration pathways. The investor roster extends to prominent angel participants: Monaco CEO Sam Blond and Jerod Mayo, the former head coach of the New England Patriots and Super Bowl champion, underscoring cross-sector interest in healthcare supply chain efficiency.
Hike Medical's core value proposition centers on three integrated layers: AI-powered back-office automation to streamline administrative workflows, point-of-care clinical tools deployed at patient touchpoints, and proprietary in-house manufacturing capabilities. Management claims this architecture delivers measurable operational improvements—shorter patient wait times, reduced remake rates (a significant cost driver in orthotics and prosthetics), and enhanced personalization of device-based care. The company positions itself at the intersection of clinical outcomes and supply chain efficiency, a combination that addresses both provider economics and patient access constraints that have long plagued the DME sector.
The funding announcement reflects broader venture investor appetite for healthcare infrastructure plays targeting regulatory-protected, recurring-revenue markets. The DME sector, anchored by Medicare/Medicaid reimbursement frameworks and physician referral volumes, offers structural demand insulation. Hike's focus on automation and manufacturing integration addresses a specific pain point: the fragmented vendor ecosystem and manual processes that have historically extended care delivery timelines and inflated operational costs for providers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.